X
SMMT icon

Xponance’s Summit Therapeutics SMMT Stock Holding History

Xponance’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$319K Buy
21,888
+1,813
+9% +$32.1K ﹤0.01% 1363
2026
Q1 		$381K Buy
20,075
+2,572
+15% +$41.6K ﹤0.01% 1147
2025
Q4 		$306K Buy
17,503
+460
+3% +$8.65K ﹤0.01% 1166
2025
Q3 		$352K Buy
17,043
+407
+2% +$9.87K ﹤0.01% 1088
2025
Q2 		$354K Buy
+16,636
New +$379K ﹤0.01% 1076

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Xponance's SMMT Position: Q2 2026 in Review

Xponance increased its Summit Therapeutics (SMMT) stake by 9% in Q2 2026, buying an estimated $32.1K and bringing the position to 21,888 shares worth $319K. The position accounts for ﹤0.01% of the portfolio, ranked #1363.

Xponance first reported a position in SMMT in Q2 2025 and has held it in 5 quarters since. The position peaked at $381K in Q1 2026. 242 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

  • Xponance held 21,888 shares of Summit Therapeutics worth $319K as of Q2 2026.
  • Xponance bought 1,813 Summit Therapeutics shares in Q2 2026, an estimated $32.1K.
  • Summit Therapeutics made up ﹤0.01% of Xponance's portfolio in Q2 2026, its #1363 holding.
  • Xponance first reported a position in Summit Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • Xponance's Summit Therapeutics position peaked at $381K in Q1 2026.
  • 242 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on Xponance's 13F filing for Q2 2026, filed 10 Aug 2026.